Search Results

Your search for William H. Sharfman, MD,William H. Sharfman, MD matches 2 pages

Showing 1 - 2

By William H. Sharfman, MD / December 10, 2018

Encorafenib and Binimetinib: A New Benchmark in Metastatic Melanoma Therapy?

IN JULY 2018, the U.S. Food and Drug Administration (FDA) approved the combination of the oral BRAF inhibitor encorafenib (Braftovi) and the oral MEK inhibitor binimetinib (Mektovi) for BRAF V600E– or V600K– positive metastatic melanoma. The FDA approval was based on the results of the COLUMBUS...

skin cancer

By The ASCO Post Staff / November 25, 2016

Johns Hopkins Awards Professorship to Melanoma Researcher

William H. Sharfman, MD, has been awarded the first Mary Jo Rogers Professorship in Cancer Immunology and Melanoma Research at Johns Hopkins University. Dr. Sharfman is Associate Professor of Oncology and Dermatology, Director of Cutaneous Oncology, Clinical Co-Director of the Johns Hopkins...

Dec

Today In Oncology

Search Results

Your search for William H. Sharfman, MD,William H. Sharfman, MD matches 2 pages

Encorafenib and Binimetinib: A New Benchmark in Metastatic Melanoma Therapy?

Johns Hopkins Awards Professorship to Melanoma Researcher

Study Finds Daratumumab Monotherapy Prevented or Delayed Progression From Smoldering to Active Multiple Myeloma

Study Finds Genetic Changes, Elevated Leukemia Risk in Ground Zero First Responders

MRI First Strategy May Be Safe for Prostate Cancer Detection

Addition of SBRT to Systemic Therapy May Improve Outcomes in Select Patients With Locally Advanced Hepatocellular Carcinoma

Epcoritamab Monotherapy for Pretreated Relapsed or Refractory CLL